Difference between revisions of "Team:Fudan-CHINA"

Line 3: Line 3:
 
<head>
 
<head>
 
<meta charset="utf-8">
 
<meta charset="utf-8">
 +
<title>Team:Fudan-CHINA -2018.igem.org</title>
 
<style type="text/css">
 
<style type="text/css">
−
body {
+
body {
−
background-color: #E7E7E7;!important;
+
background-color:rgba(21,101,126,1.00);!important;
−
}
+
    }
 +
.step{font-family:Algerian;
 +
  font-size: 1100%;
 +
  color: white;
 +
  left: 800px;
 +
  position: absolute;
 +
  top: 230px;
 +
}
 +
.abstract{
 +
font-family:Baskerville, "Palatino Linotype", Palatino, "Century Schoolbook L", "Times New Roman", "serif";
 +
color: white;
 +
font-size: 160%;
 +
position: absolute;
 +
width: 1500px;
 +
left: 200px;
 +
top: 600px;
 +
;
 +
}
 +
.fullname{
 +
font-family:Cambria, "Hoefler Text", "Liberation Serif", Times, "Times New Roman", "serif";
 +
color: white;
 +
    font-size: 200%;
 +
position: absolute;
 +
left:800px;
 +
top:430px;
 +
}
 +
p{text-indent:50px;
 +
}
 +
 +
 +
 
</style>
 
</style>
 
</head>
 
</head>
 +
 
<body>
 
<body>
−
<img src="https://static.igem.org/mediawiki/2018/c/c6/T--Fudan-CHINA--background2.jpg" >
+
<img src="https://static.igem.org/mediawiki/2018/1/1d/T--Fudan-CHINA--step_white.png" width="250" height="250" style="position:absolute; left:500px; top:250px;">
−
<table width="1200" border="0" align="center" bgcolor="#e7e7e7">
+
<div class="step">S T E P</div>
−
  <tbody>
+
<div class="abstract">
−
    <tr>
+
<p>Cell therapy has shown great potential in cancer treatment these years, while the existing CAR-T cell therapy can only target on cell surface antigens. </p>
−
      <td><h1>STEP</h1>
+
<p>However, there are also many tumour markers free in the blood, also being important targets marking the location of tumour. Here we manage to construct a brand new transducer system, named STEP, to recognise small, soluble tumour markers (e.g. VEGF, AFP, TSGF).</p>
−
</td>
+
<p>For that purpose, we adapt and optimise a newly developed system to transduce the input (free ligands) into release of a transcription factor and expression of desired drugs. To increase the recognition ability, we use Rosetta to redesign the interface between ligand and receptor in order to enhance the binding affinity. </p>
−
    </tr>
+
<p>Our STEP system can be applied for detecting tumour markers in blood and secrete drug in real time to appropriate tissues, providing a new yet practical approach for cell therapy and cancer treatment.</p>
−
    <tr>
+
</div>
−
      <td><p>iGEM 2018 team:Fudan-CHINA </p></td>
+
<div class="fullname">
−
    </tr>
+
Synthetic Transducer Engineering Platform
−
    <tr>
+
</div>
−
      <td><h3>Description</h3></td>
+
−
    </tr>
+
−
    <tr>
+
−
      <td> Synthetic Transducer Engineering Platform (STEP) </td>
+
−
    </tr>
+
−
    <tr>
+
−
      <td>As the primary cause of death, cancer has long been threatening life of human. Modular receptor systems have become a hotspot of cancer therapy, while existing synthetic systems (CAR-T, synNotch, etc) are only capable of recognising membrane protein rather than soluble ligands, which are also important targets. To address this problem, we designed Synthetic Transducer Engineering Platform (STEP), which is aimed to convert extracellular stimulation of soluble ligands into a reporter gene signal. STEP consists of two separate transmembrane chains, one with an intracellular domain of a transcription factor and the other with a protease. Binding of ligands and the two chains will lead to a cleavage event and release the transcription factor, thus triggering desired gene expression, e.g., secretion of drugs. With its extra- and intra-cellular domain being highly programmable, STEP provides a general yet orthogonal platform of ligand recognition, and a new approach of targeting therapy of cancer. </td>
+
−
    </tr>
+
−
  </tbody>
+
−
</table>
+
−
<img src="https://static.igem.org/mediawiki/2018/f/f2/T--Fudan-CHINA--membrane.gif" width="1920">
+
 
</body>
 
</body>
 
</html>
 
</html>

Revision as of 15:15, 15 September 2018

Team:Fudan-CHINA -2018.igem.org
S T E P

Cell therapy has shown great potential in cancer treatment these years, while the existing CAR-T cell therapy can only target on cell surface antigens.

However, there are also many tumour markers free in the blood, also being important targets marking the location of tumour. Here we manage to construct a brand new transducer system, named STEP, to recognise small, soluble tumour markers (e.g. VEGF, AFP, TSGF).

For that purpose, we adapt and optimise a newly developed system to transduce the input (free ligands) into release of a transcription factor and expression of desired drugs. To increase the recognition ability, we use Rosetta to redesign the interface between ligand and receptor in order to enhance the binding affinity.

Our STEP system can be applied for detecting tumour markers in blood and secrete drug in real time to appropriate tissues, providing a new yet practical approach for cell therapy and cancer treatment.

Synthetic Transducer Engineering Platform